HR Execs on the Move

Swanky Smiles

www.swankysmiles.com

 
Swanky Smiles started with just one question... What if orthodontics was designed around YOU? We are a mobile orthodontic business specializing in the greatest orthodontic technology in the world. Invisalign. While you get to enjoy our crazy convenient services of not only coming to you for all of your appointments, and being open 7 days a week for 12 hours a day.. You can relax knowing your orthodontic treatment receives all the same benefits, if not more, with Swanky Smiles. --- Swanky Smiles currently services 40+ cities in the U.S.
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million
  • www.swankysmiles.com
  • 1825 NE 45th Street Suite A
    Fort Lauderdale, FL USA 333308
  • Phone: 303.495.2883

Executives

Name Title Contact Details

Similar Companies

Crittenton Hospital Medical Center

Crittenton Hospital Medical Center is dedicated to enhancing the health status of the individuals that it serves.

Teva Neuroscience

Teva Neuroscience is one of the leading providers in Healthcare, Pharmaceuticals, & Biotech. It is based in Kansas City, MO. To find more information about Teva Neuroscience, please visit www.tevaneuro.com

ABK Biomedical

ABK Biomedical Inc. combines a compelling clinical market need with innovative biomaterials invented by Drs. Bob Abraham, Daniel Boyd and Sharon Kehoe.

Vision Events

Vision Events is a Bedford, NH-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Clarvista Medical

ClarVista Medical` based in Aliso Viejo` California is a leading developer of innovative products to treat challenging ophthalmic conditions. In 2012 and in conjunction with series A financing` ClarVista was spun out from Prospex Medical` a medical device incubator` to pursue the development of the HARMONI™ IOL. Between 2012 and 2014` the company developed the first generation HARMONI™ system` conducted thorough first-in-human clinical study and developed a broad portfolio of intellectual property. In 2015 the company closed on a series B financing of $14M which will be used to develop the second generation HAROMONI™ system` conduct a larger feasibility clinical trial and obtain key regulatory approvals including CE mark and US IDE.